RT Journal
A1 Hingorani AD, Psaty BM
T1 MOdeling cardiovascular disease prevention—reply
JF JAMA
JO JAMA
YR 2010
FD March 3
VO 303
IS 9
SP 835
OP 835
DO 10.1001/jama.2010.189
UL http://dx.doi.org/10.1001/jama.2010.189
AB 
Although many of the estimates needed to populate decision models are already available, there has been relatively little comparative work on the performance and cost-effectiveness of available screening tests and risk scores. Also, the preferences of populations that might be targeted for primary prevention have yet to be adequately evaluated. The wide cost differential between generic and proprietary statins also needs to be considered.